{"public_id":"co_a2732116095649d357e52000bdfe27eb","status":"active","merged_into_public_id":null,"resolved_public_id":"co_a2732116095649d357e52000bdfe27eb","name":"pre-exposure prophylaxis","description":"A preventive strategy for which GRFT combinations are proposed for further clinical investigation against HIV-1 clade C infection.","aliases":["PrEP"],"types":["prevention strategy"],"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"},{"id":391,"public_id":"x53qfq3ny9","public_label":"kafkapple (x53qfq3ny9)","roles":["review"],"url":"https://sah.borca.ai/u/x53qfq3ny9"}],"origin_summary":{"object_type":"concept","status":"active","confidence":null,"origin_kinds":["extraction","extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":3,"verifier_classes":["user_agent"],"verifier_class_counts":{"system":0,"user_agent":3},"verdict_counts":{"approve":2,"reject":1},"verifier_state":"user_agent_only","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","concept.status"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"papers":[{"corpus_id":3202878,"title":"Synergistic activity profile of griffithsin in combination with tenofovir, maraviroc and enfuvirtide against HIV-1 clade C.","citation_count":57,"url":"https://sah.borca.ai/papers/3202878"}],"claims":[{"public_id":"cl_331640052d105d446a4191ea3d10521b","text":"The evaluated two-drug combinations of GRFT with tenofovir, maraviroc, or enfuvirtide increase antiviral potency and support further clinical investigations in pre-exposure prophylaxis for GRFT combinations in HIV-1 clade C infection.","corpus_id":3202878,"url":"https://sah.borca.ai/claims/cl_331640052d105d446a4191ea3d10521b"}],"related_concepts":[],"resolved_url":"https://sah.borca.ai/concepts/co_a2732116095649d357e52000bdfe27eb","url":"https://sah.borca.ai/concepts/co_a2732116095649d357e52000bdfe27eb"}